NDA 017962 · Esjay Pharma
Parlodel
Bromocriptine Mesylate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Jun 28, 1978
Approved uses
2
Original approval plus efficacy supplements
Registered trials
47
13 Phase 3, 3 recruiting
FAERS reports
522
444 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 27, 2026.
Bromocriptine mesylate is an ergot derivative indicated for the treatment of: Hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility, or hypogonadism in adults (1.1) Prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older (1.2). Acromegaly in adults (1.3). Signs and symptoms of idiopathic Parkinson’s disease or postencephalitic parkinsonism in adults (1.4). Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions (1.1, 5.4) 1.1 Hyperprolactinemia-Associated Dysfunction Bromocriptine mesylate is indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility or hypogonadism in adults. Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4)]. 1.2 Prolactin-Secreting Adenomas Bromocriptine mesylate is indicated for the treatment of prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older. 1.3 Acromegaly Bromocriptine mesylate is indicated for the treatment of acromegaly in adults. 1.4 Idiopathic Parkinson’s Disease or Postencephalitic Parkinsonism Bromocriptine mesylate is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease or postencephalitic parkinsonism in adults.
Mechanism: Bromocriptine mesylate contains bromocriptine, an ergot derivative and dopamine receptor agonist, which activates post-synaptic dopamine receptors. Dopaminergic neurons in the tuberoinfundibular process release dopamine that modulates the secretion of prolactin from the anterior pituitary; in the corpus striatum the dopaminergic neurons are involved in the control of motor function. Bromocriptine induces stereotyped behavior in rodents and turning behavior in rats (e.g., rats move in circles) that have unilateral lesions in the substantia nigra. These actions, characteristic of those produced...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 28, 1985 Supplement 18 · Efficacy
- Jun 28, 1978 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- PARLODEL · BROMOCRIPTINE MESYLATE EQ 2.5MG BASE · TABLET, ORAL · Prescription · TE AB
- PARLODEL · BROMOCRIPTINE MESYLATE EQ 5MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bromocriptine" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability Study of Cycloset in Treatment of Type 2 DiabetesPivotal-lookingCompleted
VeroScienceIndustry
NCT00377676 · 3,095 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: Cycloset; Usual Diabetes Therapy plus placebo · For: Type 2 Diabetes Mellitus
- PRolaCT - Three Prolactinoma RCTsPivotal-lookingStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04107480 · 880 participants (planned) · Start Jun 21, 2019 · Primary completion Mar 31, 2024
Drug: Dopamine Agonists · For: Prolactinoma; Prolactin-Producing Pituitary Tumor
Sites: Amsterdam-Zuidoost, Netherlands; Delft, Netherlands; Leiden, Netherlands
Boehringer IngelheimBoehringer Ingelheim
NCT02233023 · 705 participants · Start Jun 1998 · Primary completion Jun 2000
Drug: Pramipexole; Bromocriptine and other dopamine agonists · For: Parkinson Disease
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00605683 · 679 participants · Start Nov 2007 · Primary completion Jan 2012
Drug: Safinamide (as add-on therapy); Safinamide (as add-on therapy) and 1 more · For: Idiopathic Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Oxnard, California · 125 sites in all
- Surgical and Pharmacological Efficacy of Knosp Grade 0-2 ProlactinomaPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06556186 · 600 participants (planned) · Start Oct 1, 2024 · Primary completion Mar 31, 2027
Drug: Bromocriptin 2.5mg, 2-3 times a day · For: Pituitary Tumor
- Study on Therapy of Non-invasive ProlactinomaPivotal-lookingStatus unknown
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT03353025 · 394 participants (planned) · Start Jan 1, 2016 · Primary completion Dec 31, 2025
Drug: dopamine agonist treatment · For: Prolactinoma
Sites: Guangzhou, China
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate TabletsPivotal-lookingRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07124221 · 382 participants (planned) · Start Sep 12, 2025 · Primary completion Nov 21, 2026
Drug: Cabergoline tablets; Bromocriptine mesylate tablets · For: Hyperprolactinemia
Sites: Beijing, China
- Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02172573 · 315 participants · Start Apr 1999 · Primary completion Jul 2000
Drug: Pramipexole; Bromocriptine and 2 more · For: Parkinson Disease
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea34
- drug ineffective31
- headache30
- pyrexia29
- vomiting28
- drug exposure during pregnancy25
- neuroleptic malignant syndrome24
- fatigue21
- dizziness20
- tremor19
- blood creatine phosphokinase increased18
- malaise17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 30 |
| 2006 | 34 |
| 2007 | 33 |
| 2008 | 37 |
| 2009 | 15 |
| 2010 | 18 |
| 2011 | 62 |
| 2012 | 55 |
| 2013 | 8 |
| 2014 | 9 |
| 2015 | 10 |
| 2016 | 19 |
| 2017 | 20 |
| 2018 | 8 |
| 2019 | 14 |
| 2020 | 4 |
| 2021 | 12 |
| 2022 | 16 |
| 2023 | 24 |
| 2024 | 41 |
| 2025 | 13 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Editorial: Bromocriptine.
· Lancet 1975 · Clinical Trial
- Dopamine agents for hepatic encephalopathy.
Junker AE, Als-Nielsen B, Gluud C, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Bromocriptine in Parkinsonism.
Calne DB, Teychenne PF, Claveria LE, et al. · Br Med J 1974 · Clinical Trial, Randomized Controlled Trial
- Prolactin secretion in Parkinson disease.
Eisler T, Thorner MO, MacLeod RM, et al. · Neurology 1981 · Clinical Trial, Randomized Controlled Trial
- Treatments for suppression of lactation.
Oladapo OT, Fawole B · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Hypoprolactinemia and ovarian function.
Kauppila A, Martikainen H, Puistola U, et al. · Fertil Steril 1988 · Clinical Trial, Randomized Controlled Trial
Sponsor: Esjay Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.